Glenmark Pharmaceuticals gets ANDA approval for Bendamustine Hydrochloride for Injection

From USFDA

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration for Bendamustine Hydrochloride for Injection, 25 mg/ vial and 100 mg/ vial, the therapeutic equivalent to the reference listed drug product, Treanda for Injection, 25 mg/ vial and 100 mg/vial, of Cephalon Inc. This marks, Glenmark's first injectable granted approvals by the USFDA.

Powered by Capital Market - Live News